Comparative Pharmacology
Head-to-head clinical analysis: HYDROPANE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPANE versus ORETIC.
HYDROPANE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
50–100 mg orally once daily, maximum 200 mg daily
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic